The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 17, 2024
Filed:
Jan. 31, 2023
Applicant:
Seattle Children's Hospital, Seattle, WA (US);
Inventor:
Michael Jensen, Bainbridge, WA (US);
Assignee:
Seattle Children's Hospital, Seattle, WA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C07K 16/46 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 35/17 (2013.01); A61K 38/179 (2013.01); A61K 47/6849 (2017.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/468 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15043 (2013.01); Y02A 50/30 (2018.01);
Abstract
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.